Literature DB >> 6111821

A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.

L E DeLisi, C D Wise, T P Bridge, J E Rosenblatt, R L Wagner, J Morihisa, C Karson, S G Potkin, R J Wyatt.   

Abstract

Platelet monoamine oxidase activity (MAO) was studied serially over time in 16 chronic schizophrenic patients when medication free and then when medicated. Thirteen of the 16 patients had significant decreases in platelet MAO activity following neuroleptic drug treatment. The change in MAO activity was found to be correlated with response to treatment and to dose of medication.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6111821     DOI： 10.1016/0165-1781(81)90013-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  5 in total

1.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

2.  Low platelet MAO activity in chronic schizophrenics: a long-term effect of neuroleptic treatment?

Authors:  M Del Vecchio; M Maj; A D'Ambrosio; D Kemali
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

3.  Platelet monoamine oxidase activity and schizophrenia--a myth that refuses to die?

Authors:  A Fleissner; R Seifert; K Schneider; W Eckert; B Fuisting
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

Review 4.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Pursuit of the "truth" about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past.

Authors:  Lynn E DeLisi
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.